Establishment of therapeutic strategy for renal cell carcinoma based on the evaluation by FDG PET/CT
Phase 2
Recruiting
- Conditions
- advanced renal cell carcinoma
- Registration Number
- JPRN-UMIN000008141
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
patients who have serious illness in heart, lung, liver, or kidney
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association of the evaluation by FDG PET/CT and progression-free survival and overall survival
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does FDG PET/CT metabolic heterogeneity correlate with VHL/HIF/mTOR pathway activation in JPRN-UMIN000008141 advanced RCC?
What is the comparative efficacy of FDG PET/CT-guided therapies versus standard TKIs/ICIs in JPRN-UMIN000008141 RCC patients?
Which biomarkers (e.g., HIF-1α, VEGF) predict response to FDG PET/CT-based strategies in clear cell RCC subtypes?
What adverse events are associated with FDG PET/CT-driven treatment selection in advanced RCC and how are they managed?
How does FDG PET/CT imaging compare to other modalities in guiding targeted therapies for non-clear cell RCC subtypes?